Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.34 |
| ▸ | HTR2C | P28335 | 3/20 | 0.34 |
| ▸ | HTR2B | P41595 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.31 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1261973 | 0.98 | HTR2A (0.33) | HTR2AHTR2CHTR2BSMN1; SMN2L3MBTL1 | |
| SCHEMBL8257616 | 0.89 | HTR2A (0.46) | HTR2AHTR2CHTR2BSMN1; SMN2L3MBTL1 | |
| SCHEMBL3394063 | 0.89 | HTR2A (0.32) | HTR2AHTR2CHTR2BSMN1; SMN2L3MBTL1 | |
| Hydrochloric Acid SCHEMBL1263416 | 0.87 | HTR2A (0.45) | HTR2AHTR2CHTR2BSMN1; SMN2L3MBTL1 | |
| Hydrochloric Acid SCHEMBL1261366 | 0.87 | HTR2A (0.32) | HTR2AHTR2CHTR2BSMN1; SMN2L3MBTL1 | |
| SCHEMBL4387393 | 0.81 | PNMT (0.36) | HTR2AHTR2CHTR2BADRB2HTR1B | |
| SCHEMBL1497107 | 0.81 | HTR2A (0.36) | HTR2AHTR2CHTR2BADRB2HTR1B | |
| SCHEMBL1970467 | 0.81 | HTR2A (0.36) | HTR2AHTR2CHTR2BSMN1; SMN2L3MBTL1 | |
| Hydrochloric Acid SCHEMBL1262763 | 0.80 | HTR2A (0.35) | HTR2AHTR2CHTR2BSMN1; SMN2L3MBTL1 | |
| SCHEMBL3389240 | 0.79 | HTR2A (0.37) | HTR2AHTR2CHTR2BSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2011-07-07 | — | — | US | disclosed |
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2011-07-07 | — | — | US | disclosed |
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2011-07-07 | — | — | US | disclosed |
| EP-2334689-A2 | FUSED HETEROCYCLIC COMPOUND | LG Life Sciences Ltd. (KR) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010027236-A2 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010027236-A2 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | F2, PF4, F11 | HTR2A 3057/4885HTR2C 3065/4885HTR2B 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.